Infant botulism …

Felicia Gliksman DO MPH FAAN

General Child Neurology

Updated 04.05.2024
Released 07.12.1994
Expires For CME 04.05.2027

Infant botulism

Author: Felicia Gliksman DO MPH FAAN

See Contributor Disclosures

Editor: Ann Tilton MD

Infant botulism

In This Article

Quick Link

Introduction

Overview

Infant botulism is serious bacterial infection that results from ingestion of Clostridium botulinum spores that colonize the intestinal tract, releasing botulinum toxin resulting in progressive neuromuscular weakness (constipation, bulbar dysfunction, flaccid descending paralysis, and respiratory failure). Treatment includes urgent administration of botulinum immune globulin (BabyBIG^®), which has been shown to shorten the course of the disorder as measured by the duration of mechanical ventilation, hospitalization, and tube feedings. If you suspect your patient has botulism, notify your state public health department. BabyBIG^® can be obtained from the California Department of Health Services (phone 510-231-7600). Supportive care is also emphasized given potential complications, including respiratory failure. Most infants recover without sequelae. In this article, the author discusses the clinical manifestations, diagnosis, and therapy of infant botulism.

Key points

	• Infant botulism presents with a progression of symptoms: constipation; cranial nerve palsies (weak cry, poor feeding, ptosis); flaccid descending paralysis; and possible respiratory failure.
	• Symptoms result from ingestion of Clostridium botulinum spores that colonize the intestinal tract and produce botulism toxin (most commonly A and B).
	• Botulism toxin binds irreversibly to presynaptic terminals, preventing release of acetylcholine and, thus, preventing muscle contraction.
	• Treatment includes urgent administration of botulism immune globulin (BabyBIG^®) as well as supportive care.
	• BabyBIG^® can be obtained from the California Department of Health Services (phone 510-231-7600).

Historical note and terminology

Human botulism has three major forms: (1) food-borne botulism, caused by ingesting preformed botulinum toxin; (2) wound botulism, due to direct infection with the bacterium Clostridium botulinum; and (3) infant botulism, caused by ingestion of C botulinum spores and subsequent production of the toxin within the infant gastrointestinal tract (67). Additionally, iatrogenic botulism secondary to clinical botulinum toxin injection, such as for treatment of spasticity, has been described in case reports (56). Increasingly, the use of botulinum toxin as an agent for bioterrorism is also a concern.

Before effective food processing, food-borne botulism was a major cause of acute paralysis and death. In 1897, Van Ermengen isolated the spore-forming, gram-positive anaerobe, Bacillus botulinum (later named Clostridium botulinum; botulism is derived from the Latin, botulus, for "sausage") from the spleen of an outbreak victim and from contaminated ham. Van Ermengen recognized that food-borne botulism originates from ingestion of preformed toxin rather than from direct infection with an enteric pathogen.

Wound and food-borne botulism remained the only disorders attributed to C botulinum until the early 1970s, when acute weakness in infants was linked to enteric colonization with the organism. This disorder, named infant botulism, caused acute bulbar and systemic weakness and respiratory failure (34; 52; 57; 09; 71). As food-borne outbreaks of botulism have declined, infant botulism is now the most common form of human botulism in the developed world (04; 51; 67). Infant botulism accounts for approximately 63% of botulism cases reported to local and state health departments in the United States (19).

Clinical manifestations

Presentation and course

Infant botulism usually occurs in previously healthy, full-term infants, most often between 6 weeks and 6 months of age (range of reports 6 days to 1 year). Symptoms typically evolve over a period of days to even a week, with a clinical nadir reached at 1 to 2 weeks. Constipation and cranial nerve palsies (commonly manifesting as drooling, poor feeding, or a weak cry) are often the earliest symptoms, followed by a flaccid descending paralysis (73). A case series revealed poor feeding and lethargy to be the most common symptoms prompting presentation (23). In a chart review of 44 infants with infant botulism, 43 of the infants were admitted for poor feeding, generalized weakness, and hypotonia with a range of symptoms from 0 to 22 days prior to admission (72).

Affected infants experience the abrupt or gradual onset of systemic weakness and bulbar dysfunction, manifested by inactivity, hypotonia, weak cry, poor suck, and reduced oral intake. Infants with infant botulism appear “lethargic” or apathetic to their parents or care providers because of their ptosis, inactivity, and paucity of facial expression. Most infants have constipation, and several days may pass between bowel movements. Systemic muscle weakness and respiratory distress become major features as the disease progresses. Though diaphragmatic function is thought to be preserved until 90% involvement (23), respiratory failure can occur abruptly. A case report of an infant diagnosed with respiratory syncytial virus but persistent respiratory failure, cranial nerve palsies, and subsequent stool + for botulinum toxin A emphasizes the importance of considering infant botulism within the differential diagnosis for these signs and symptoms despite other confirmed diagnoses (59).

Botulinum toxin does not cross the blood-brain barrier, and there are no associated central nervous system symptoms, nor consequences.

Examination of the infant with botulism reveals ptosis, facial weakness, feeble cry, poor suck, reduced or absent gag reflex, poor head control, diffuse hypotonia, weakness, and reduced or absent muscle stretch reflexes (70). The pupils are usually dilated and react sluggishly to light (22). Sluggish pupil response, however, may take continually repeating the exam for 2 to 3 minutes to elicit constrictor muscle fatigability. Fever is characteristically absent.

Antitoxin effect from BabyBIG^® is reported to neutralize botulinum toxin for 6 or more months (08).

Prognosis and complications

Many infants with botulism require mechanical ventilation due to respiratory failure or difficulty handling oral secretions. Prior to the availability of botulism immune globulin, the duration of assisted ventilation was 3 or more weeks (62). In a randomized controlled trial of botulism, immune globulin treatment reduced the mean duration of mechanical ventilation by 2.6 weeks (08). Clinical guidelines published by the CDC in 2021 recommend administration of botulinum antitoxin to patients with suspected botulism as early as possible in the course of illness. The greatest benefit accrues to those who receive it within the first 2 days of illness onset (60). Infants require nasojejunal feedings until they recover bulbar function and can appropriately feed and protect their airways (70).

Relapse occurs in approximately 5% of infants with botulism, usually within 2 weeks of recovery from the initial illness (30).

Clinical recovery occurs over a period of weeks to months, but full clinical recovery is expected.

Clinical vignette

A previously healthy 4-month-old male infant was brought to the emergency department for lethargy and reduced oral intake. There was no family history of serious systemic or neurologic disease. Presentation in the emergency department revealed an inactive infant with normal vital signs, afebrile. General examination showed no heart murmurs, organ enlargement, rash, or dysmorphic features. Neurologic examination showed bilateral ptosis, weak cry, diminished gag, and diffuse hypotonia with poor head control. Pupils were midrange and sluggishly reactive to light. Muscle stretch reflexes were present but diminished; sensation was intact to light touch and noxious stimuli. His parents remarked that he normally had excellent head control and previously cried vigorously when examined. His last bowel movement was 5 days earlier.

Laboratory studies included normal complete blood cell count, urinalysis, and serum electrolytes, calcium, and magnesium. Electrodiagnostic studies showed a 40% increment during rapid stimulation. Stool studies were subsequently positive for both C botulinum organism and toxin (type A). He was admitted to the hospital, treated with botulism immune globulin (BabyBIG^®), and provided with aggressive supportive measures; he recovered well.

Biological basis

Etiology and pathogenesis

Infant botulism results from toxin produced by swallowed spores most commonly of Clostridium botulinum and rarely of C butyricum or C baratti. Etiology of infant botulism is distinctly different from food-borne botulism (the ingestion of a preformed toxin) or wound botulism (from inoculation of the bacteria into a wound). Ingestion of honey is a common association, but spores are also found in aerosolized particles from soils (such as construction sites or rural locations) and house dust.

Botulinum toxin is formed under anaerobic conditions by Clostridium species, ubiquitous spore-forming organisms found in soils and households. Seven serotypes (types A through G) of toxin have been identified (51; 67). Types A, B, E, and F are associated with human disease (38); types A and B produce the majority of cases of infant botulism (50; 51). Luquez and colleagues reported a case of infant botulism due to Clostridium botulinum type E (49). From 1976 to 2016, C baratii type F caused more than 0.5% of cases occurring mostly in very young infants with a more rapid and severe illness compared to types A and B (36). In 2014, Barash and Arnon reported the first new strand of Botulinum neurotoxin (type H) in over 40 years, isolated from a fecal sample of an infant with botulism (10).

Rarely, enteric colonization during broad spectrum antibiotic therapy in adults leads to clinical botulism (12; 51; 33; 67).

Once ingested, C botulinum spores can colonize the large intestine of infants, multiply, and produce toxin (53; 67). Because of competitive inhibition by other microorganisms, C botulinum is not part of the normal intestinal microflora (03). Clostridia sp are excluded from the gut of breastfed infants, but the addition of solid foods can result in colonization (29). This accounts for cases of infant botulism in breastfed infants who become colonized with C botulinum during introduction of other foods (03; 47). Once absorbed, the toxin is carried hematogenously to the neuromuscular junctions (51). Botulinum toxin in infant botulism has not been reported to cross the blood-brain barrier into the CNS.

The C botulinum toxin, a complex protein similar to the tetanus toxin, is among the most potent of neurotoxins (54). It is synthesized as a large 150 kd protein and consists of two disulfide-bonded fragments. The larger 100 kd heavy chain fragment of the botulinum toxin binds irreversibly to specific receptors in the axon terminus of cholinergic motor neurons, leading to an inability of motor neurons to release acetylcholine from the presynaptic terminal in response to an action potential (66). Structural analysis reveals binding of botulinum toxin type B to synaptotagmin II and specific ganglioside receptors (20). Data have indicated that antigenic peptides at the heavy-chain terminal contain the binding sites to the receptor synaptotagmin II, allowing for botulinum toxin type B binding (65). After binding, the toxin is then translocated and exerts intracellular effects to prevent the release of acetylcholine into the neuromuscular junction.

Various host factors also seem to be important as C botulism spores are more commonly ingested than clinical disease produced (15). A report of a 4-month-old infant with H1N1 influenza and subsequent diagnosis of infant botulism may support the theory of impaired host response; alternatively, this case could have already had exposure to the botulism spores prior to development of influenza as the botulism incubation period in the gut ranges from 3 to 30 days (40). The effects of toxin binding at the neuromuscular junction and other cholinergic nerve terminals, such as the intestine, produce the clinical manifestations of muscle weakness and constipation (72).

The precise biological events that lead to clinical recovery in human infants are unclear because botulinum toxin persists in stool samples during and after resolution of clinical symptoms (06; 47). In fact, a case report presented a 3-month-old infant with persistent excretion of C botulinum cells in stool samples for 7 months following diagnosis of type A infant botulism despite symptoms resolution occurring within 2 months (25). Recovery appears to require axonal transport of proteins from the perikaryon and regeneration of new motor end plates (51). Morphologically, recovery is associated with new sprouting from the presynaptic terminal in the neuromuscular junction. Given the need for regeneration of terminal motor neurons and formation of motor end plates, complete clinical recovery is expected to take weeks to months.

Epidemiology

In 2018, a total of 242 cases of infant botulism were reported, which accounted for 67% of all total cases of botulism reported to the National Botulism Surveillance Summary System (19). Of those, 43% were type A toxin, 54% type B toxin, 1% Ba toxin, 2% Bf toxin, and <1% F toxin. Affected infants ranged in age from 0 to 10 months (median of 4 months). Infant botulism has been recognized in all regions of the United States, 31 states (18; 67; 19), and on all continents except Africa (04; 44). Cases of infant botulism in the United States cluster in certain geographic regions, with California (23%) and Pennsylvania (17%) reporting the most (19). Although cases can occur year-round, the prevalence tends to be highest in the summer and fall (05; 70). Type A is found predominately west of the Mississippi River and type B predominately east of the Mississippi River. Type F has been reported in various regions of the United States (36).

Globally, infant botulism is thought to be under-recognized and under-reported. Evaluating the global occurrence from 1976 to 2006, 26 countries on five continents, in addition to the United States, had reports of infant botulism. The most frequent cases of infant botulism outside of the United States occur in Argentina, Australia, Canada, Italy, and Japan (44). In the United Arab Emirates, there is a case report of an infant with “double toxin” botulism type Ba (26). In Italy, four of the 23 cases reported between 1984 and 2005 were secondary to C Butyricum, type E neurotoxin and 73% after reported honey ingestion (27). France has noted an increase in reports of infant botulism over the past 6 years, citing seven cases between 2004 and 2009 (43). Globally, type A toxin was reported most commonly, in nearly 85% of cases, followed by type B toxin (10%), and rarely type E toxin (44).

Although cases can cluster geographically (70), point source outbreaks of infantile botulism do not occur. There are no reported cases of infant-to-infant transmission of infant botulism. Exposure to the organism is the major risk factor, as indicated by an increased relative risk among early cases following dietary exposure to honey (odds ratio 9:8) or corn syrup (odds ratio 5:2), items that can contain C botulinum spores (68). Exposure to these foods explained 16% to 30% of the early cases (07; 68), but honey and corn syrup have been implicated in less than 10% of the recently described cases in the United States (70; 08). C botulinum spores have been detected in 7.5% of Chamomile tea samples in Argentina, often used in herbal remedies, which could be a potential vector for infant botulism (14). PCR analysis of a random collection of honey samples in Turkey revealed 2.6% positive samples, three type A and one type B toxin, suggesting continued potential risk for infant botulism exposure (35). In Ireland, infant botulism (C butyricum neurotoxin type E) was associated with exposure from pet terrapins (64).

Risk factors may vary according to the age of the infant. Rural residence and exposure to aerosolized soils are risk factors (71; 70; 05; 68). Longstanding constipation and breastfeeding are controversial risk factors. As constipation is an early symptom, it is difficult to attribute a causal role. In infants exclusively breast fed, the changes in intestinal microflora that occur when formula or solid foods are introduced may play a role in the ability of C botulinum to colonize the infant's colon (70). The majority of the Pennsylvania cases reported by Long and colleagues occurred within 4 weeks of the initial introduction of non-breast milk foods (47). Reported findings of soil-dwelling Clostridia sporogenes and Clostridia butyricum in samples of powdered infant formula indicate the risk of the potential presence of Clostridia botulinum in powdered infant formula products (11). Neither botulism bacteria nor toxin are able to pass through breast milk, thus, maternal ingestion of honey or maternal infection with food-borne botulism are not thought to be risk factors in the development of infant botulism.

Infant botulism was once postulated to be a factor in the pathogenesis of sudden infant death syndrome (SIDS) (51). In one large series, toxin or organism was recovered in 4.9% of 211 cases of sudden infant death (05). However, both disorders occur in infants between the ages of 2 and 6 months, suggesting that the relationship may be coincidental rather than causal. An Australian study failed to identify C botulinum in cases of SIDS (16).

Differential diagnosis

Infants with botulism have clinical features that suggest bacterial sepsis or meningitis. Other disorders that can be associated with acute weakness include electrolyte disorders, such as extreme hyponatremia, hypokalemia or hyperkalemia, hypomagnesemia or hypermagnesemia, hypothyroidism, hypocalcemia or hypercalcemia, thiamine deficiency, and inborn errors of metabolism, especially disorders of the urea cycle, organic acid metabolism, or fatty acid oxidation defects.

Other considerations include spinal muscular atrophy, infantile Guillain-Barré syndrome, tick paralysis, poliomyelitis, mitochondrial disorders, glutaric aciduria type II, and infantile Pompe syndrome. Spinal muscular atrophy is suggested by areflexia, tongue fasciculations, and chronicity of signs and symptoms. Furthermore, spinal muscular atrophy typically spares the ocular muscles. Both spinal muscular atrophy and Guillain-Barré syndrome can be distinguished from infant botulism by distinctive electrophysiologic features. Although the Miller Fisher variant of Guillain-Barré syndrome involves cranial nerve palsies, this disorder can be distinguished by CSF analysis, nerve conduction studies, and EMG findings. Eradicated from the United States and most regions of the world, poliomyelitis can be distinguished from infant botulism by antecedent gastroenteritis, fever, signs of aseptic meningitis, and the presence of asymmetric weakness. Infants with mitochondrial disorders have elevated serum lactate and often distinctive abnormalities on brain MRI. It is also important to consider toxic exposures such as organophosphate or heavy metal poisoning.

Rarely, unrecognized congenital myasthenia gravis mimics infant botulism. Like infants with botulism, infants with myasthenia gravis have ocular involvement (rarely with pupillary abnormalities, however) and bulbar weakness. The response to edrophonium chloride or neostigmine can be confusing, as infants with botulism may transiently improve after administration of these agents. The response to rapid repetitive stimulation of motor nerves (24) and the recovery of C botulinum toxin from the stool samples can distinguish these two disorders.

Five categories of clinical mimics were described based on 681 cases from 1992-1997. These “mimics” occurred in 4.7% of infants in whom the laboratory diagnosis of infant botulism was not confirmed and include: (1) spinal muscular atrophy, (2) metabolic disorders, (3) other infectious diseases (ie, enterovirus encephalitis, RSV bronchiolitis, viremia), (4) miscellaneous (ie, Miller Fisher variant of Guillain-Barré syndrome, presumed Lambert Eaton syndrome, cerebral atrophy and infarctions, idiopathic spinal epidural hematoma, diaphragmatic paralysis and central demyelinating disease), and (5) probable infant botulism (28). Reported potential surgical mimics include Hirschsprung disease (55) and presentation of an acute abdomen (58).

In a follow-up report by Khouri and colleagues in 2018, 1226 patients were treated with BIG-IV from 2005 to 2015, of which 76 (6.2%) clinical mimic illnesses were identified (42). These were also divided into the same categories listed above. The distribution revealed (1) probable infant botulism lacking confirmatory testing (26.3%); (2) spinal muscular atrophy (19.7%); (3) miscellaneous (15.8%) (ie, abnormalities in gray/white matter and corpus callosum, acute disseminated encephalomyelitis, transverse myelitis, Chiari malformation, cystic fibrosis, hypovitaminosis A, hemophilia A, cervical epidural hemorrhage, hypothyroidism, nemaline rod myopathy, and Miller-Fischer variant or pharyngeal-cervical-brachial variant of Guillain Barre Syndrome); (4) metabolic disorders (11.8%); and (5) other infectious diseases (10.6%) (human metapneumovirus, parainfluenza, parechovirus, roseola, polio-like enterovirus, likely resolved sepsis). No alternate diagnosis was established in 15.8%, and these were, therefore, categorized as undetermined.

Diagnostic workup

Infants with botulism have C botulinum spores and toxin in their stools. Detection of toxin confirms the diagnosis of infant botulism, whereas detection of organisms only establishes colonization. Affected infants commonly have reduced stooling, necessitating saline enemas for effective stool sampling. Stool can remain positive for culture and toxin for extended periods, although infants may clear the organisms within 1 month of diagnosis (39). It is recommended to collect stool specimens for laboratory confirmation of the clinical diagnosis of botulism as soon as possible because toxin levels decrease over time (60).

The current standard of organism and toxin detection is through a toxin neutralization mouse bioassay. Polymerase chain reaction methods can be used to detect toxin, but the sensitivity and specificity of polymerase chain reaction have not yet been established (69; 41; 01). Glyco-qPCR detection is another rapid analysis technique being explored (45). Several other diagnostic techniques are being explored, including ELISA, endopeptidase activity assay, biosensors, cell-based assay, mass spectrometry, lateral flow, rolling circle amplification, and other techniques reviewed (46; 17; 37).

Potentially life-threatening systemic or CNS infections should be considered in infants with acute weakness and hypotonia. Appropriate cultures of blood, urine, and CSF should be obtained. Serum electrolytes, calcium, magnesium, thyroid, lactate, and ammonia should also be considered. Specimens for toxicology and metabolic studies may be appropriate, depending on the clinical history. A spinal tap is often indicated, but this procedure must be performed carefully because prolonged neck and trunk flexion may provoke respiratory failure.

Imaging of the brain and spine is often not indicated, but when reported, is typically normal/negative. However, Good and colleagues reported a case of a 5-month-old infant that presented clinically with features of infant botulism (ultimately confirmed with mouse bioassay), but had abnormalities on brain MRI (areas of white matter diffusion restriction) and spine MRI (symmetrical cervical nerve root enhancement) (31). This infant responded rapidly to BabyBIG^®, and the authors noted that neuroimaging findings should not preclude treatment in patients with a clinical presentation consistent with infant botulism.

Although largely a clinical diagnosis, infant botulism can be supported by electrophysiologic studies. An incremental response to rapid (20 or 50 Hz) repetitive stimulation is the most sensitive and specific finding (70). Slower rates of repetitive stimulation yield variable responses and confusing results (24). Needle electromyography is also sensitive but less specific, and many infants have short-duration, low-amplitude motor unit potentials and abnormal spontaneous activity (22; 24). False negative or positive EMG results can be observed (32; 70). A review of 14 patients with infant botulism revealed brief, small amplitude potentials as the most common EMG abnormality (72).

Management

Human botulism immune globulin (BIG-IV, known as BabyBIG^®) shortens the clinical course of infant botulism as measured by the durations of intensive care, mechanical ventilation, hospitalization, and intravenous tube feedings (63; 02; 70; 08; 73; 60).

The Committee on Infectious Diseases of the American Academy of Pediatrics recommends that BabyBIG^® be administered as soon as the diagnosis of infant botulism is suspected, without waiting for laboratory confirmation (02; 73). BabyBIG^® can be obtained from the California Department of Health Services (phone 510-231-7600). Information can also be obtained at www.infantbotulism.org.

The half-life of BabyBIG^® is approximately 28 days, and a single infusion is reported to neutralize toxin for 6 months (08). Although botulism immune globulin is typically given within 2 weeks of symptoms and is most effective within 72 hours (08), there is report of effective, rapid response as late as 23 days after presentation (26). Nevertheless, BabyBIG^® should be given as soon as infant botulism is clinically suspected, ideally within 2 days (60).

The primary adverse event associated with BabyBIG® was a transient erythematous rash. No other adverse events were more common in the BabyBIG® group when compared to the placebo-treated group (08; 73). The Cochrane Collaboration released a report indicating good evidence to support the use of BabyBIG® in the treatment of infant botulism (21).

As the cost of BabyBIG^® limits use in other countries, equine botulinum antitoxin has been documented as a safe, effective alternative (74).

Infants with botulism require meticulous supportive care (02). The major threat to infants with botulism is respiratory failure. Consequently, affected infants should be monitored closely in an intensive care setting; they should be intubated and ventilated when signs of airway compromise, bulbar dysfunction, or respiratory insufficiency arise. Sedation for scans or other procedures should be given very cautiously. Untreated infants with botulism may require ventilation for several weeks (75; 08).

Infants may experience altered autonomic function, including sudden unexplained alterations in heart rate, blood pressure, or skin color. Symptoms of autonomic dysfunction are usually mild or transient and rarely require specific therapy (47). Urinary retention may require intermittent catheterization. A small number of infants experience the syndrome of inappropriate antidiuretic hormone secretion, especially early in the disorder after being placed on positive pressure ventilators. This responds to fluid restriction and usually resolves spontaneously.

Constipation responds to stool softeners, digital manipulation, and enemas. Despite their extreme constipation, most infants with botulism tolerate enteral feedings well. Because of the potential for aspiration, nasojejunal feedings are preferred over nasogastric. Most infants can be adequately nourished by continuous nasojejunal feedings, beginning as early as 3 days after presentation (62). Feeding should not be resumed until the infant has normal gag, suck, swallow, and airway protection.

Antibiotics may result in increased toxin release, and aminoglycosides further impair release of acetylcholine, both worsening neuromuscular blockade (72). If possible, broad spectrum antibiotics should be avoided. Despite transient improvement with intravenous edrophonium or intramuscular neostigmine, acetylcholinesterase inhibitors do not have sustained benefit.

A case report suggests an association between thiamine deficiency and severity of infant botulism symptoms, as thiamine is required for acetylcholine synthesis, and recommends consideration of thiamine supplementation (61).

Finally, after administration of BabyBIG^®, immunizations should be delayed until the infant has regained full muscle strength/tone, and live viruses should be delayed 5 months (www.infantbotulism.org).

Outcomes

Unless respiratory failure and death occur during the acute stage of the disorder, infants with botulism recover completely. During the acute phase, nearly all infants will have compromised respiratory function, and approximately 50% of patients presenting with infant botulism require mechanical ventilation (70; 08). Two factors that have been reported to be associated with respiratory decompensation include use of aminoglycoside antibiotics, which further decreases release of acetylcholine, and neck flexion for procedures (15).

The syndrome of inappropriate antidiuretic hormone can be observed in some infants (47), necessitating periodic assessment of serum electrolytes. Secondary infections, including otitis media and pneumonia, are common in severely ill infants requiring various degrees of life support (62). Urinary retention and constipation are frequent associated complications. Relapse occurs in approximately 5% of infants with proven botulism, usually within 2 weeks after initial recovery (30). However, after administration of BabyBIG^®, neutralizing toxin persists for 6 months or more, thus, making recurrence unlikely. Parents should be reassured that their infants will recover completely, despite the prospects of a prolonged hospitalization.

References

01: Akbulut D, Grant KA, McLauchlin J. Development and application of real-time PCR assays to detect fragments of the Clostridium botulinum types A, B, and E neurotoxin genes for investigation of human foodborne and infants botulism. Foodborn Pathog Dis 2004;1:247-57. PMID 15992287
02: American Academy of Pediatrics. Clostridial infections. In: Pickering LK, editor. 2003 red book: report of the Committee on Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003:243-6.
03: Arnon SS. Infant botulism. In: Borriello, editor. Clostridia in gastrointestinal disease. Boca Raton, FL: CRC Pr, 1985:40-55.
04: Arnon SS. Infant botulism: anticipating the second decade. J Infect Dis 1986;154:201-6. PMID 3522756
05: Arnon SS, Damus K, Chin J. Infant botulism: epidemiology and relation to sudden infant death syndrome. Epidemiol Rev 1981;3:45-66. PMID 7030764
06: Arnon SS, Midura TF, Clay SA, Wood RM, Chin J. Infant botulism: epidemiological, clinical, and laboratory aspects. JAMA 1977;37:1946-51. PMID 321825
07: Arnon SS, Midura TF, Damus K, Thompson B, Wood RM, Chin J. Honey and other environmental risk factors for infant botulism. J Pediatr 1979a;94:331-8. PMID 368301
08: Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:462-71. PMID 16452558
09: Arnon SS, Werner SB, Faber HK, Farr WH. Infant botulism in 1931. Am J Dis Child 1979b;133:580-2. PMID 375716
10: Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014;209(2):183-91. PMID 24106296
11: Barash JR, Hsia JK, Arnon SS. Presence of soil-dwelling clostridia in commercial powdered infant formulas. J Pediatr 2010;156(3);402-8. PMID 20004414
12: Bartlett JC. Infant botulism in adults. N Engl J Med 1986;315:254-6. PMID 3523249
13: Benjamins LJ, Gourishankar A, Yataco-Marquez V, Cardona EH, de Ybarrondo L. Honey pacifier use among an indigent pediatric population. Pediatrics 2013;131(6):e1838-41. PMID 23650307
14: Bianco MI, Luquez C, de Jong LIT, Fernandez RA. Presence of Clostridium botulinum spores in Matricaria chamomilla (chamomile) and its relationship with infant botulism. Int J Food Microbiol 2008;121:357-60. PMID 18068252
15: Brook I. Infant botulism. J Perinatol 2007;27:175-80. PMID 17314986
16: Byard RW, Moore L, Bourne AJ, Lawrence AJ, Goldwater PH. Clostridium botulinum and sudden infant death syndrome: at ten-year prospective study. J Pediatr Child Health 1992;28:156-7. PMID 1562366
17: Cai S, Singh BR, Sharma S. Botulism diagnostics: from clinical symptoms to in vitro assays. Crit Rev Microbiol 2007;33:109-25. PMID 17558660
18: Centers for Disease Control. Notifiable diseases, 1992. MMWR Morb Mortal Wkly Rep 1993;42:537.
19: Centers for Disease Control. National Surveillance Team – Enteric Diseases Epidemiology Branch. Accessed 2019. Council of State and Territorial Epidemiologists Botulism Surveillance Summary. 2016.
20: Chai Q, Arndt JW, Dong M, et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006;444:1096-100. PMID 17167418
21: Chalk C, Benstead TJ, Keezer M. Medical treatment for botulism. Cochrane Database Syst Rev 2014;2:CD008123. PMID 24558013
22: Clay SA, Ramseyer JC, Fishman LS, Sedgwick RP. Acute infantile motor unit disorder, infant botulism. Arch Neurol 1977;34:246-9. PMID 320969
23: Clemmens MR, Bell I. Infant botulism presenting with poor feeding and lethargy. Pediatr Emerg Care 2007;23(7):492-4. PMID 17666936
24: Cornblath DR, Sladky JT, Sumner AJ. Clinical electrophysiology of infantile botulism. Muscle Nerve 1983;6:448-52. PMID 6312310
25: Derman Y, Korkeala H, Salo E, Lonnqvist T, Saxen H, Lindstrom M. Infant botulism with prolonged faecal excretion of botulinum neurotoxin and Clostridium botulinum for 7 months. Epidemiol Infect 2014;142(2):335-9. PMID 23688392
26: Fathalla WM, Mohammed KA, Ahmed E. Infant botulism type Ba: first culture-confirmed case in the United Arab Emirates. Pediatr Neurol 2008;39:204-6. PMID 18725068
27: Fenicia L, Anniballi F, Aureli P. Intestinal toxemia botulism in Italy, 1984-2005. Eur J Clin Microbiol Infect Dis 2007;26:385-94. PMID 17516104
28: Francisco AM, Arnon SS. Clinical mimics of infant botulism. Pediatrics 2007;119:826-8. PMID 17403857
29: George WL, Finegold SM. Clostridia in the human gastrointestinal flora. In: Borriello, editor. Clostridia in gastrointestinal disease. Boca Raton, FL: CRC Pr, 1985:2-37.
30: Glauser TA, Maguire HC, Sladky JT. Relapse of infant botulism. Ann Neurol 1990;28:187-9. PMID 2221848
31: Good RJ, Messacar K, Stence NV, Press CA, Carpenter TC. Abnormal neuroimaging in a case of infant botulism. Front Pediatr 2015;3:108. PMID 26697417
32: Graf WD, Hays RM, Astley SJ, Mendelman PM. Electrodiagnosis reliability in the diagnosis of infant botulism. J Pediatr 1992;120:747-9. PMID 1315854
33: Griffin PM, Hatheway CL, Rosenbaum RB, Sokolow R. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization of botulism and underlying Crohn's disease. J Infect Dis 1997;175:633-7. PMID 9041335
34: Grover WD, Peckham GJ, Berman PH. Recovery following cranial nerve dysfunction and muscle weakness in infancy. Dev Med Child Neurol 1974;16:163-71. PMID 4365404
35: Gucukoglu A, Terzi G, Cadirci O, Alisarli M, Kevenk O, Uyanik T. Detection of C. Botulinum types in honey by mPCR. J Food Sci 2014;79(4):M600-3. PMID 24621137
36: Halpin AL, Khouri JM, Payne JR, et al. Type F infant botulism: investigation of recent clusters and overview of this exceedingly rare disease. Clin Infect Dis 2017;66(suppl_1):S92-4. PMID 29293930
37: Hansbauer EM, Skiba M, Endermann T, et al. Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry. Analyst 2016;141(18):5281-97. PMID 27353114
38: Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol 1995;195:55-75. PMID 8542759
39: Hatheway CL, McCroskey LM. Examination of feces and serum for diagnosis of infant botulism in 336 patients. J Clin Microbiol 1987;25:2334-8. PMID 3323228
40: Hyslop AE, Droker BS, Jansen LA. Clinical reasoning: an unexpected diagnosis in a 4-month-old infant with lethargy and H1N1 influenza. Neurology 2011;76(18):e88-92. PMID 21536632
41: Kakinuma H, Maruyama H, Yamakawa K, et al. Application of nested polymerase chain reaction for the rapid diagnosis of infant botulism type B. Acta Pediatr Jpn 1997;39:346-8. PMID 9241898
42: Khouri JM, Payne JR, Arnon SS. More clinical mimics of infant botulism. J Pediatr 2018;193:178-82. PMID 29229451
43: King LA, Popoff MR, Mazuet C, Espié E, Vaillant V, de Valk H. [Infant botulism in France, 1991-2009.] Arch Pediatr 2010;17(9):1288-92. PMID 20724121
44: Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics 2008;122:73-82. PMID 18595978
45: Kwon SJ, Jeong EJ, Yoo YC, et al. High sensitivity detection of active botulinum neurotoxin by glyco-quantitative polymerase chain-reaction. Anal Chem 2014;86(5):2279-84. PMID 24506443
46: Lindstrom M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev 2006;19:298-314. PMID 16614251
47: Long SS. Epidemiologic study of infant botulism in Pennsylvania: report of the infant botulism study group. Pediatrics 1985;75:928-34. PMID 3991282
48: Long SS, Gajewski JL, Brown LW, Gilligan PH. Clinical, laboratory and environmental features of infant botulism in southeastern Pennsylvania. Pediatrics 1985;75:935-41. PMID 3887319
49: Luquez C, Dykes JK, Yu PA, Raphael BH, Maslanka SE. First report worldwide of an infant botulism case due to Clostridium botulinum type E. J Clin Microbiol 2010;48(1):326-8. PMID 19906896
50: Midura TF. Laboratory aspects of infant botulism in California. Rev Infect Dis 1979;1:652-4. PMID 399372
51: Midura TF. Update: Infant botulism. Clin Microbiol Rev 1996;9:119-25. PMID 8964030
52: Midura TF, Arnon SS. Identification of Clostridium botulinum and its toxin in faeces. Lancet 1976;2:934-6. PMID 62164
53: Mills DC, Arnon SS. The large intestine as the site of Clostridium botulinum colonization in human infant botulism. J Infect Dis 1987;156:997-8. PMID 3316418
54: Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 1995;28:423-72. PMID 8771234
55: O’Reilly EB, Montenegro B, Arnold J, Tomita S. Infant botulism mimicking Hirschprung’s disease. J Pediatr Surg 2009;44(10):e5-7. PMID 19853738
56: Partikian A, Mitchell WG. Iatrogenic botulism in a child with spastic quadriparesis. J Child Neurol 2007;22(10):1235-7. PMID 17940253
57: Pickett J, Berg B, Chaplin E, Brunstetter-Shafer MA. Syndrome of botulism in infancy: clinical and electrophysiologic study. N Engl J Med 1976;295:770-2. PMID 785257
58: Pisanti R, Vitiello R, Formicola S, Pisanti A. Infant botulism mimicking an acute abdomen. Infez Med 2009;17(4):254-6. PMID 20046108
59: Quinn KK, Cherry JD, Shah NR, Christie LJ. A 3-month-old boy with concomitant respiratory syncytial virus bronchiolitis and infant botulism. Pediatr Infect Dis J 2013;32(2):195. PMID 23328826
60: Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm Rep 2021;70(2):1-30.** PMID 33956777
61: Ringe H, Schuelke M, Weber S, Dorner BG, Kirchner S, Dorner MB. Infant botulism: is there an association with thiamine deficiency? Pediatrics 2015;134(5):e1436-40. PMID 25311602
62: Schreiner MS, Field E, Ruddy R. Infant botulism: a review of 12 years' experience at the Children's Hospital of Philadelphia. Pediatrics 1991;87:159-65. PMID 1898989
63: Schwartz PJ, Arnon SS. Botulism immune globulin for infant botulism arrives--one year and a gulf war later. West J Med 1992;156:197-8. PMID 1536081
64: Shelley EB, O’Rourke D, Grant K, et al. Infant botulism due to C. butyricum type E toxin: a novel environmental association with pet terrapins. Epidemiol Infect 2015;143(3):461-9. PMID 25306863
65: Shi J, Bao S, Yin J, et al. Dominant antigenic peptides located at the heavy chain terminal of botulinum neurotoxin B contain receptor-binding sites for synaptotagmin II. Biochem Biophys Res Comm 2008;373:331-5. PMID 18639519
66: Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Ann Rev Pharmacol Toxicol 1986;26:427-53. PMID 3521461
67: Sobel J. Botulism. Clin Infect Dis 2005;41:1167-73. PMID 16163636
68: Spika JS, Shaffer N, Hargrett-Bean N, Collin S, MacDonald KL, Blake PA. Risk factors for infant botulism in the United States. Am J Dis Child 1989;143:828-32. PMID 2741856
69: Szabo EA, Pemberton JM, Gibson AM, Eyles MJ, Desmarchelier PM. Polymerase chain reaction for detection of Clostridium botulinum types A, B and E in food, soil and infant faeces. J Appl Bacteriol 1994;76:539-45. PMID 8027003
70: Thompson JA, Filloux FM, VanOrman CB, et al. Infant botulism in the age of botulism immune globulin. Neurology 2005;64:2029-32. PMID 15917401
71: Thompson JA, Glasgow LA, Warpinski JR , et al. Infant botulism: clinical spectrum and epidemiology. Pediatrics 1980;66:936-42. PMID 7005856
72: Tseng-Ong L, Mitchell WG. Infant botulism: 20 years’ experience at a single institution. J Child Neurol 2007;22:1333-7. PMID 18174547
73: Underwood K, Rubin S, Deakers T, Newth C. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Children’s Hospital Los Angeles. Pediatrics 2007;120:1380-5. PMID 18055655
74: Vanella de Cuetos EE, Fernandez RA, Bianco MI, et al. Equine botulinum antitoxin for the treatment of infant botulism. Clin Vaccine Immunol 2011;18(11):1845-9. PMID 21918119
75: Wohl DL, Tucker JA. Infant botulism: considerations for airway management. Laryngoscope 1992;102:1251-4. PMID 1405986

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Felicia Gliksman DO MPH FAAN

Dr. Gliksman of Hackensack University Medical Center and Hackensack Meridian Health School of Medicine at Seton Hall University has no relevant financial relationships to disclose.
See Profile

Editor

Ann Tilton MD

Dr. Tilton has received honorariums from Allergan and Ipsen as an educator, advisor, and consultant.
See Profile

Former Authors

Michael V Johnston MD†
Thomas Crawford MD (original author), James F Bale Jr MD, and Sarah R Risen MD

Patient Profile

Age range of presentation: 0 to 23 months
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: Caucasians
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Infant botulism

Differential Diagnosis

bacterial sepsis
viral sepsis
meningitis
electrolyte disturbances
hyponatremia
- hypokalemia
- hyperkalemia
- hypomagnesemia
- hypermagnesemia
- hypocalcemia
- hypercalcemia
- thiamine deficiency
- inborn errors of metabolism
- disorders of the urea cycle
- disorders of organic acid metabolism
- fatty acid oxidation defects
- poliomyelitis
- spinal muscular atrophy
- mitochondrial disorders
- aseptic meningitis
- Guillain-Barré syndrome
- congenital myasthenic syndrome

Infant botulism …

Infant botulism

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Breath-holding spells

Neuropathies associated with cytomegalovirus infection

Acute cerebellar ataxia in children

Clinical evaluation of peripheral neuropathies

Zika virus: neurologic complications

Cerebral edema in childhood

Malformations of the brain

Hypothyroidism

Infant botulism

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

Special considerations

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Breath-holding spells

Neuropathies associated with cytomegalovirus infection

Acute cerebellar ataxia in children

Clinical evaluation of peripheral neuropathies

Zika virus: neurologic complications

Cerebral edema in childhood

Malformations of the brain

Hypothyroidism

This is an article preview.
Start a Free Account
to access the full version.